Yohei Takumi
Overview
Explore the profile of Yohei Takumi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karashima T, Takamori S, Abe M, Takumi Y, Osoegawa A, Sugio K
Surg Today
. 2025 Feb;
PMID: 40014076
Purpose: To assess the safety and efficacy of neoadjuvant chemoradiotherapy with cisplatin plus S-1 for advanced non-small cell lung cancer (NSCLC), with a focus on real-world outcomes. Methods: This retrospective...
2.
Takamori S, Osoegawa A, Hashinokuchi A, Karashima T, Takumi Y, Abe M, et al.
Chest
. 2024 Jul;
166(5):1218-1228.
PMID: 39004218
Background: The eighth edition of lung cancer nodal staging assignment includes the location of lymph node metastasis, but does not include single-nodal and multiple-nodal descriptors. Research Question: Do the single-nodal...
3.
Abe M, Osoegawa A, Karashima T, Takamori S, Takumi Y, Sugio K
J Thorac Dis
. 2024 Jul;
16(6):3553-3562.
PMID: 38983136
Background: Based on the results of JCOG0802 and CALGB studies, segmentectomy has considered to be a standard procedure for early-stage non-small cell lung cancer (NSCLC). After lobectomy, the residual cavity...
4.
Hashimoto T, Osoegawa A, Abe M, Oki R, Karashima T, Takumi Y, et al.
Int Cancer Conf J
. 2024 Jul;
13(3):204-208.
PMID: 38962043
The patient was a 74-year-old woman who was diagnosed with lung adenocarcinoma, clinical Stage IIIA. Induction chemoradiation was performed followed by right upper lobectomy and lymph node dissection. Because of...
5.
Sakaguchi H, Tanimoto A, Sato S, Yanagimura N, Suzuki C, Takumi Y, et al.
Med Int (Lond)
. 2024 Jun;
1(4):8.
PMID: 38939364
The present study aimed to evaluate the clinical benefits of leucovorin, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) vs. gemcitabine plus Nab-paclitaxel (GnP) as a first-line therapy for patients with inoperable pancreatic...
6.
Osoegawa A, Abe M, Miyawaki M, Karashima T, Takumi Y, Takamori S, et al.
Ann Thorac Cardiovasc Surg
. 2023 Nov;
30(1).
PMID: 38030280
Purpose: Robot-assisted thoracic surgery (RATS) has become popular because of its minimally invasive nature and reduced burden on surgeons. The anterior approach (AA) is beneficial because it utilizes the same...
7.
Osoegawa A, Karashima T, Takumi Y, Sato T, Abe M, Hashimoto T, et al.
J Thorac Dis
. 2023 Nov;
15(10):5566-5573.
PMID: 37969303
Background: Although osimertinib was approved as adjuvant therapy for lung cancer patients with mutation in various countries, there is still some ongoing debate as osimertinib has been approved based on...
8.
Miyawaki M, Karashima T, Abe M, Takumi Y, Hashimoto T, Kamohara R, et al.
J Cardiothorac Surg
. 2023 Nov;
18(1):328.
PMID: 37964272
Background: Intrathoracic neurogenic tumors arise from sympathetic nerve trunks and intercostal nerves; more than 90% are benign. Schwannomas are the most common histological variety, but fatalities due to giant schwannomas...
9.
Osoegawa A, Abe M, Takumi Y, Hashimoto T, Karashima T, Miyawaki M, et al.
Thorac Cancer
. 2023 Jul;
14(24):2467-2472.
PMID: 37455369
Background: Several studies have reported that the high expression of programmed death-ligand 1 (PD-L1) within tumor cells predicts a poor prognosis. However, the relationship between the PD-L1 expression and lymph...
10.
Osoegawa A, Takumi Y, Hashimoto T, Nakatsuji S, Hori M, Sakai M, et al.
Invest New Drugs
. 2023 Feb;
41(2):183-192.
PMID: 36790603
Background: Lung cancer is the leading cause of cancer death worldwide, and EGFR mutation is the most common genetic alteration among Asian patients with lung adenocarcinoma. While osimertinib has been...